Table 2 Clinical and parasitological outcome of Plasmodium vivax affected patients treated with combined doses of CQ–PQ for 14 days (T14) or with an intermittent single dose (ISD)

Single dose

 Clinical outcome (% with symptoms)

  Fever

10.17^†

3.70^†

1.8^†

0

0

0

  Headache

30.51^†

16.67^†

3.7^†

5.3^†

3.3^†

0

  Mialgias

1.69^†

3.39^†

0

0

0

0

  Arthralgias

0

0

0

0

0

0

  Blisters

5.08

6.78

7.41

3.7

1.8

0

  Erythema/pruritus

10.17

8.47

1.85

0

0

0

  Light jaundice

11.86

13.56*

11.11*

9.2*

3.6

0

 Asexual parasitaemia by microscopy

  Positivity: n, %^a

14, 23.7

3, 5.0

0

0

0

2, 3.4

 p/µl^b: median (IQR)^c

62 (68)

157.7 (59.1)

–

–

–

223 (163)

% PCR positive^d

41.3

12.7

0

0

0

3.4

14-day (T14)

 Clinical outcome (% with symptoms)

  Fever

2.67^†

3.17^†

0

0

0

0

  Headache

25.33^†

7.94^†

0

2.2^†

0

0

  Mialgias

2.47^†

4.0^†

0

0

0

0

  Arthralgias

1.23

1.33

0

0

0

0

  Blisters

3.70

4.0

3.17

0

0

0

  Erythema/pruritus

7.41

9.33

6.35

4.1

0

0

  Light jaundice

23.46

32.0*

36.5*

40.8*

13.6

2.2

 Asexual parasitaemia by microscopy

  Positivity: n, %^a

13, 16

4, 5.1

0

0

0

0

  p/µl^b: median (IQR)^c

118 (180)

42.4 (43.0)

–

–

–

–

  % PCR positive^d

34.1

8.75

0

0

0

0